pfizer glp-1 drug 2 Companies Poised to Capitalize on the Rise of Weight Loss Drugs Pfizer pulls out of GLP-1

Preclinical studies have confirmed that GIPRGLP1R coagonists improve several hallmarks of metabolic syndrome, such as obesity, hyperglycemia, and dyslipidemia

Berberine has been studied

A new Phase 2 trial at Johns Hopkins testing the GLP-1 drug pegsebrenatide in progressive MS may finally explain why adults on diabetes medications for a decade show measurably slower brain shrinkage

Nevertheless, more comprehensive studies are needed regarding the long-term efficacy, safety profiles, and clinical positioning of these agents

By including all English-language studies on muscle mass loss during GLP-1RA therapy in T2D and obesity from major scientific databases and clinical trial registries, this narrative review synthesizes the current knowledge on the epidemiology and mechanisms of muscle loss in diabetes and obesity, with a focus on the impact of GLP-1RAs therapy

Additionally, several key clinical trial readouts delivered compelling data across multiple indications, for example (see Figure 1): Semaglutide: STEP-HFpEF (functional benefits in HFpEF), STEP-9 (pain reduction in knee osteoarthritis), STEP-10 (reversion to normoglycaemia in pre-diabetic, obese patients), ESSENCE (resolution of MASH, improvement in fibrosis) Tirzepatide: SUMMIT (risk reduction in HFpEF outcomes